Anti-allergic properties of the natural PAF antagonist yangambin.
In this study we examined the ability of the furofuran lignan yangambin to influence the local and systemic responses induced by antigen or PAF in actively sensitized or normal rats. Given intraperitoneally 1 h before stimulation, yangambin inhibited the pleural neutrophil and eosinophil infiltration evoked by the i.pl. injection of PAF or antigen into normal or 14 daysensitized rats whereas plasma exudation evoked by both stimuli was unaffected. The pleural neutrophil influx (6 h) after LTB4 stimulation was also significantly inhibited by yangambin. We also evidenced that the hemoconcentration, thrombocytopenia, and leucocytosis noted after i.v. PAF were all attenuated by yangambin. In actively sensitized rats, pretreatment with yangambin failed to modify the antigen-induced hemoconcentration and leucocytosis, but dose-dependently abrogated the thrombocytopenia noted 1 h post-stimulation. In vitro, the anaphylactic contraction of longitudinal jejunal segments to antigen challenge was significantly inhibited by yangambin (10(-5)-10(-4) M). Likewise, the contraction of jejunal segments from normal rats to PAF was markedly blocked by yangambin under conditions where the response to 5-hydroxytryptamine (5-HT) was not altered. In conclusion, our results show that antigen- and PAF-induced pleural neutrophil and eosinophil accumulation, but not exudation, is sensitive to treatment with yangambin. In addition, yangambin also suppressed the pleural neutrophil infiltration triggered by LTB4 as well as the blood thrombocytopenia and intestinal anaphylaxis elicited by antigen in rats. Thus, our findings indicate that yangambin shows an antagonistic action on receptors other than those of PAF, i.e., LTB4, and strongly suggest that it may be a useful drug in the treatment of some allergic inflammatory responses.
Serra
M F
MF
Departamento de Fisiologia e Farmacodinämica, Instituto Oswaldo Cruz/FIOCRUZ, Rio de Janeiro, Brazil.
Diaz
B L
BL
Barreto
E O
EO
Pereira
A P
AP
Lima
M C
MC
Barbosa-Filho
J M
JM
Cordeiro
R S
RS
Martins
M A
MA
de Silva
P M
PM
D000818:Animals; D018926:Anti-Allergic Agents; D004804:Eosinophils / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005663:Furans / Q000494:pharmacology*; D007964:Leukocytosis / Q000139:chemically induced / Q000517:prevention & control; D017705:Lignans / Q000494:pharmacology*; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D010936:Plant Extracts; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors* / Q000633:toxicity; D010998:Pleurisy / Q000139:chemically induced / Q000276:immunology / Q000517:prevention & control; D051381:Rats; D017208:Rats, Wistar; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control
D018926:Anti-Allergic Agents; D005663:Furans; D017705:Lignans; D010936:Plant Extracts; D010972:Platelet Activating Factor; C082827:epiyangambin